Skip to main content
Journal cover image

Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.

Publication ,  Journal Article
Li, X; Huang, Y; Liu, Y; Yan, S; Li, L; Cheng, L; Li, H; Zhan, H; Zhang, F; Li, Y
Published in: Clin Rheumatol
March 2023

OBJECTIVES: The objective of the current study was to detect plasma profiles of inflammatory cytokines for determining potential biomarkers indicating cancer presence among the anti-TIF1-γ antibody-positive dermatomyositis (DM) patients. METHODS: Twenty-seven cancer-associated anti-TIF1-γ antibody-positive DM (Cancer TIF1-γ-DM) patients were compared with 20 anti-TIF1-γ antibody-positive DM patients without cancer (Non-cancer TIF1-γ-DM) and 10 healthy controls (HC). The plasma levels of 17 cytokines were determined using the Luminex 200 system. The ability of plasma VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ levels to distinguish the presence of cancer was evaluated through the area under the curve (AUC) analysis. Potential protein interactions of TIF1-γ and the five cytokines were analyzed using the STRING database. RESULTS: VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ plasma levels were significantly higher in the Cancer TIF1-γ-DM group, especially those without any anticancer treatment, than those in the non-cancer TIF1-γ-DM and HC groups. Meanwhile, anti-TIF1-γ antibody and the five cytokines could distinguish cancer presence in anti-TIF1-γ antibody-positive DM patients. The STRING network indicated that TIF1-γ potentially interacted with the cytokines. Positive correlations of VEGF-A among CCL2, IL-6, and IFN-γ and between IFN-γ and IL-6 were observed in Cancer TIF1-γ-DM patients. VEGF-A, TNF-α, CCL2, and IL-6 were positively associated with muscle-associated enzymes among the Cancer TIF1-γ-DM patients. CONCLUSION: The present study identified VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as significant potential biomarkers indicating the presence of cancer and demonstrated a more detailed cytokine profile during diagnosis. These biomarkers could provide better screening strategies and insight into the Cancer TIF1-γ-DM pathogenesis. Key Points • VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ are potential biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis. Potential pathogenic molecular mechanism of the cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.

Duke Scholars

Published In

Clin Rheumatol

DOI

EISSN

1434-9949

Publication Date

March 2023

Volume

42

Issue

3

Start / End Page

817 / 830

Location

Germany

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Tumor Necrosis Factor-alpha
  • Neoplasms
  • Interleukin-6
  • Interferon-gamma
  • Humans
  • Dermatomyositis
  • Cytokines
  • Chemokine CCL2
  • Biomarkers
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, X., Huang, Y., Liu, Y., Yan, S., Li, L., Cheng, L., … Li, Y. (2023). Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis. Clin Rheumatol, 42(3), 817–830. https://doi.org/10.1007/s10067-022-06425-3
Li, Xiaomeng, Yuan Huang, Yongmei Liu, Songxin Yan, Liubing Li, Linlin Cheng, Haolong Li, Haoting Zhan, Fengchun Zhang, and Yongzhe Li. “Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.Clin Rheumatol 42, no. 3 (March 2023): 817–30. https://doi.org/10.1007/s10067-022-06425-3.
Li, Xiaomeng, et al. “Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.Clin Rheumatol, vol. 42, no. 3, Mar. 2023, pp. 817–30. Pubmed, doi:10.1007/s10067-022-06425-3.
Li X, Huang Y, Liu Y, Yan S, Li L, Cheng L, Li H, Zhan H, Zhang F, Li Y. Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis. Clin Rheumatol. 2023 Mar;42(3):817–830.
Journal cover image

Published In

Clin Rheumatol

DOI

EISSN

1434-9949

Publication Date

March 2023

Volume

42

Issue

3

Start / End Page

817 / 830

Location

Germany

Related Subject Headings

  • Vascular Endothelial Growth Factor A
  • Tumor Necrosis Factor-alpha
  • Neoplasms
  • Interleukin-6
  • Interferon-gamma
  • Humans
  • Dermatomyositis
  • Cytokines
  • Chemokine CCL2
  • Biomarkers